Antineoplastic Agents, Hormonal
Research News and Information

Monday, November 23, 2009

A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient.

30 Oct 2009 BACKGROUND: The incidence of, and mortality from, prostate cancer (PCa) has increased in Asian countries over the past decades, partly due to a change in dietary habits. Recent reports have revealed differences in the molecular basis of PCa among ... Read more...

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

5 Oct 2009 CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the ... Read more...

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.

29 Sep 2009 Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness. Current therapies targeting the androgen receptor, including androgen-depletion approaches and anti-androgens, do not completely inhibit the ... Read more...

Latest indexed articles for 'Antineoplastic Agents, Hormonal'

These are the very latest articles for this heading:

• Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. 30 Oct 2009
• A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient. 30 Oct 2009
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. 5 Oct 2009
• Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. 29 Sep 2009
• Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. 29 Sep 2009
• [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region] 29 Sep 2009
• [Infantile haemangioma and intracranial vascular malformation] 12 Sep 2009
• Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). 7 Sep 2009
• Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Sep 2009
• Optimal therapy in localized prostate cancer: an unfolding story. 30 Aug 2009
• Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. 30 Aug 2009
• Emerging drugs for prostate cancer. 30 Aug 2009
• [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide] 30 Aug 2009
• [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer] 30 Aug 2009
• [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors] 30 Aug 2009
• External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification. 26 Aug 2009
• Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. 24 Aug 2009
• Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. 23 Aug 2009
• Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. 23 Aug 2009
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. 22 Aug 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents, Hormonal'

Definition: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Registry Number: 0

Descriptor UI: D018931

Alternative terms: Antineoplastic Agents, Hormonal; Hormonal Agents, Antineoplastic; Hormonal Antineoplastic Agents; Hormonal Antineoplastics; Antineoplastic Hormonal Drugs; Drugs, Antineoplastic Hormonal; Hormonal Drugs, Antineoplastic; Hormonal Antineoplastic Drugs; Antineoplastics, Hormonal; Antineoplastic Hormonal Agents; Agents, Antineoplastic Hormonal; Antineoplastic Drugs, Hormonal;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248.169;

History Note: 96

Technical Notes: consider also NEOPLASMS, HORMONE-DEPENDENT /drug ther